This site is intended for healthcare professionals

In an interim analysis Opdivo in CheckMate -274 met primary endpoints of disease-free survival in both all randomized patients and in patients whose tumors express PD-L1 in at least 1% of cells.- BMS

Read time: 1 mins
Last updated:16th Mar 2021
Published:26th Sep 2020
Condition: Bladder Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest